Epigenetic action of decitabine (5-aza-2′-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C)
RL Momparler, S Côté, LF Momparler - Leukemia Research, 2013 - Elsevier
Treatment of elderly patients with acute myeloid leukemia (AML) with standard cytarabine
(ARA-C) chemotherapy can achieve some complete responses (CR), but the median overall
survival is less than one year. New approaches should be investigated. The inhibitor of DNA
methylation, 5-aza-2′-deoxycytidine (decitabine, DAC), shows effectiveness in these
patients, but was not approved by the US Federal Drug Administration. This decision was
based on a clinical trial where DAC showed a median survival of 7.0 months as compared to …
(ARA-C) chemotherapy can achieve some complete responses (CR), but the median overall
survival is less than one year. New approaches should be investigated. The inhibitor of DNA
methylation, 5-aza-2′-deoxycytidine (decitabine, DAC), shows effectiveness in these
patients, but was not approved by the US Federal Drug Administration. This decision was
based on a clinical trial where DAC showed a median survival of 7.0 months as compared to …